Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-79.6	-71.58	-37.66	-51.38	-49.22	-23.46
Depreciation & Amortization	0.69	0.6	0.22	0.1	0.1	0.03
Share-Based Compensation	15.17	12.91	3.19	3.85	2.23	0.9
Other Operating Activities	-0.05	-3.2	2.18	0.67	1.63	0.65
Operating Cash Flow	-63.79	-61.27	-32.08	-46.77	-37.4	-21.88
Capital Expenditures	-0.14	-0.15	-0.61	-0.01	-0.02	-0.14
Change in Investments	-166.13	-148.26	0	-1.62	-16.7	-23.92
Investing Cash Flow	-166.27	-148.41	-0.61	-1.63	-16.72	-24.06
Share Issuance / Repurchase	88.99	161.76	0.59	49.68	81.45	0
Other Financing Activities	-1.88	72.52	-2.39	-0.58	15.43	43.58
Financing Cash Flow	87.12	234.29	-1.8	49.1	96.88	43.58
Net Cash Flow	-142.94	24.61	-34.49	0.7	42.76	-2.36
Free Cash Flow	-63.92	-61.42	-32.69	-46.78	-37.42	-22.02
Free Cash Flow Per Share	-1.52	-1.73	-10.46	-8.64	-10.75	-125.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).